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Approximately fifty million people worldwide have epilepsy, making the condition
the second leading neurological disorder. With optimal drug therapy, epilepsy is con-
trolled in about 75% of the patients, but about 10% continue to have seizures at intervals
of one month or less, since they are not responsive to conventionally available medical
therapies (1). Moreover, the current drug therapy is associated with adverse side effects
such as drowsiness, ataxia, gastrointestinal disturbance, gingival hyperplasia, hirsutism
and megaloblastic anaemia (2). In the last twenty-five years, particularly in the last de-
cade, there have been many advances relating to all aspects of epilepsy. Noteworthy has
been the progress in terms of understanding the established antiepileptic drugs (AEDs)
and introduction of several newer agents developed rationally, on the basis of available
information on the biochemical changes in the epileptic brain. Aryl semicarbazones have
documented consistent advances in the design of novel anticonvulsant agents (3–6). If
the aryl semicarbazones displaying activity in the maximal electroshock seizure (MES)
screen interact at a specific binding site, it is likely that the semicarbazone group
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(NHCONHN=) and the aryl ring, referred to as the hydrogen bonding area and the aryl
binding site, respectively, align at complementary areas on a macromolecule complex in
vivo. In addition, a number of substituted aryl ureas have exhibited potent anticonvul-
sant activity (7, 8). Substitution in the 2-position of the phenyl ring with electron-donat-
ing groups was generally beneficial to activity; exceptions appear to be those groups
which are capable of hydrogen bonding, such as the OH and NH2, where activity was
found to be reduced (9). The importance of the ortho-methyl group for anticonvulsant ac-
tivity has been emphasized in many studies (10–13), including the recently marketed
drug tiagabine. MES and subcutaneous pentylenetetrazole (scPTZ) tests have become
the two most widely employed seizure models for the early identification and high
throughput screening of investigational antiepileptic drugs. These tests, albeit extremely
effective in identifying new antiepileptic drugs that may be useful for the treatment of
human generalized tonic-clonic and generalized myoclonic seizures, may miss novel an-
tiepileptic drugs that may be useful for the treatment of therapy resistant partial seizu-
res. It is also important to note that several clinically effective drugs, including primi-
done and vigabatrin, are not capable of blocking seizures in MES and scPTZ tests (14,
15). In addition to our studies on various aryl semicarbazones (13, 16–18), the present
work is an attempt to study the effect of 2,4-dimethyl substitution on anticonvulsant ac-
tivity. Based on our recent research outcomes (19), potent compounds were studied for
their effect on -aminobutyric acid (GABA) levels in rat brain and in vitro GABA-trans-
aminase activity.
EXPERIMENTAL
Melting points were determined in one end open capillary tubes on a Büchi 530
melting point apparatus (Büchi Laboratories, Switzerland) and are uncorrected. Infrared
(IR) and proton nuclear magnetic resonance (1H NMR) spectra were recorded for the com-
pounds by using Jasco IR Report 100 (KBr) (Jasco, UK) and Brucker Avance 300 MHz in-
struments (Brucker Biospin, Germany), respectively. Chemical shifts are reported in parts
per million (ppm) using tetramethylsilane (TMS) as an internal standard. All exchange-
able protons were confirmed by addition of D2O. Elemental analysis (C, H, N) was per-
formed with a Perkin Elmer Model 240C analyser (Perkin Elmer, USA).
Synthesis of 2,4-dimethylphenyl semicarbazide hydrochloride (2)
The 2,4-dimethylphenyl urea (1) was synthesized according to the earlier reported
procedure (13). Compound 1 (11.48 g, 0.07 mol) was refluxed in ethanol with double qu-
antity of hydrazine hydrate (7 mL) for 24 h. The resultant precipitate was filtered off and
dried. 0.06 mol of 2 was dissolved in sufficient quantity of methanol by warming and 50
mL of concentrated hydrochloric acid was added slowly, and cooled in a freezer for 2 h.
The precipitate obtained was filtered off and dried (Scheme 1).
Synthesis of 2,4-dimethyl phenyl semicarbazones (3–30). General procedure.
To a solution of 2 hydrochloride (0.55 g, 0.003 mol) in methanol, an equimolar quantity
of sodium acetate in water and the appropriate aldehyde or ketone in methanol were
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added. The mixture was stirred under heating on a magnetic stirrer for 30 min and the re-
sultant precipitate was filtered off and dried. The product was recrystallized from 95% etha-
nol. The chemical and spectral data of the compounds synthesized are presented in Table I.
The synthesized compounds (Scheme 1) show characteristic absorption bands in IR
spectra: 3450, 3300–3260 (NH), 3040, 2940, 1650–1670 (CONH), 1550–1570 (C=N, imine),
1300–1400 (C-N, Ar-NH) and 835–845 cm–1. The spectral data of all the synthesized com-
pounds are presented in Table II.
Pharmacology
Male albino mice (CF-1 strain, 18–25 g, 3 months) and male albino rats (Sprague
Dawley/Wistar, 100–150 g, 6 months) were used as experimental animals. The Institu-
tional Animal Ethical Committee reviewed and approved all animal procedures. The an-
imals were housed in metabolic cages, and allowed free access to food and water. The
synthesized compounds 1–30 were suspended in a 0.5% methyl cellulose/water mixture
or in polyethylene glycol (PEG 200).
Anticonvulsant screening. – Anticonvulsant evaluations were undertaken using the
reported procedures (20–22). Initially, all compounds were administered i.p. at doses of
30, 100 and 300 mg kg–1 to one to four mice (4 animals for doses 30 and 100 mg kg–1 and
1 animal for 300 mg kg–1; if protected, tested in the remaining 3 animals (NIH standard
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protocol). Activity was established using the MES, scPTZ and subcutaneous strychnine
(scSTY) and neurotoxicity tests. Compounds 5, 6, 10–12 and 22 were challenged in the 6
Hz, 32 mA current for 3 s to examine antipsychomotor seizure activity in mice (23). The
reference compounds employed were phenytoin, carbamazepine and sodium valproate
in doses of 30, 100 and 300 mg kg–1 (i.p. in a 0.5% methylcellulose/water mixture). Some
selected derivatives described in this study were examined for oral activity in the rat
MES screen (24).
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Table I. Physical data of the synthesized compounds




1 – – 70 207–209 C9H12N2O 164.20
2 – – 67 157–159 C9H13N3O 179.22
3 H H 69 182–184 C16H17N3O 267.33
4 H 2-Cl 67 193–195 C16H16N3OCl 301.77
5 H 2-OH 88 211–213 C16H17N3O2 283.32
6 H 2-NO2 73 216–218 C16H16N4O3 312.32
7 H 3-Cl 67 194–196 C16H16N3OCl 301.77
8 H 3-NO2 57 229–231 C16H16N4O3 312.32
9 H 4-Br 97 224–226 C16H16N3OBr 346.22
10 H 4-OH 86 209–211 C16H17N3O2 283.32
11 H 4-NO2 80 251–253 C16H16N4O3 312.32
12 H 4-CH3 89 195–197 C17H19N3O 281.35
13 H 4-OCH3 77 139–141 C17H19N3O2 297.35
14 H 4-N(CH3)2 68 208–210 C18H22N4O 310.39
15 H 3-OCH3, 4-OH 75 191–193 C17H19N3O3 313.35
16 CH3 H 62 204–206 C17H20N3O 281.35
17 CH3 2-OH 68 217–219 C17H19N3O2 297.35
18 CH3 3-NH2 73 219–221 C17H20N4O 296.37
19 CH3 4-Cl 62 224–226 C17H18N3OCl 315.80
20 CH3 4-OH 53 177–179 C17H19N3O2 297.35
21 CH3 4-NO2 86 247–249 C17H18N4O3 326.35
22 CH3 4-NH2 55 184–186 C17H20N4O 296.37
23 CH3 4-CH3 68 175–177 C18H21N3O 295.38
24 C6H5 H 59 189–191 C22H21N3O 343.42
25 C6H5 4-Br 51 67–69 C22H20N3OBr 422.32
26 CH3 CH3 55 158–160 C12H17N3O 219.28
27 CH3 C2H5 57 147–149 C13H19N3O 233.31
28 CH3 CH2COCH3 56 84–86 C14H19N3O2 261.32
29 CH3 CH2CH(CH3)2 60 102–104 C15H23N3O 261.36
30 R-R1 = cyclohexyl 71 173–175 C15H21N3O 259.35
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Neurotoxicity screening. – Minimal motor impairment was measured in mice (groups
of 4) by the rotorod test. The mice were trained to stand on an accelerating rotarod rotat-
ing at 10 rpm. The rod diameter was 3.2 cm. Trained animals were given i.p. injections of
the test compounds in doses of 30, 100 and 300 mg kg–1. Neurotoxicity was indicated by
the inability of the animal to maintain equilibrium on the rod for at least 1 min in each of
the three trials.
Behavioral testing. – The titled compounds (30 mg kg–1) were screened for their be-
havioral effects using an actophotometer (25) at 30 min and 1 h after injection in each
group of six animals. The behavior of animals inside the photocell was recorded as a
digital score. Increased scores suggested good behavioral activity. The control animals
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Table III. Anticonvulsant activity and neurotoxicity (mg kg–1) of the synthesized compounds
Compound
MES screena scPTZ screena scSTY screena Toxicity screena
0.5 h 4 h 0.5 h 4 h 0.5 h 4 h 0.5 h 4 h
1 100 – 300d – – – 300 –f
2 100 – 300d –e – – 100 100
5 – –c – – – – 300 –
9 – – 300 – 100 300 300 100
10 –c – – – – – – –
12 300 300 – – 75 75 300 –
23 – – – – 100 100 – 300
25 300b – 300d – 150 150 300 –
26g 100 300 300d 300b 300 300 100f 300
27g 300 – 300d – 100 – 300 –
28 – – –d – – – – –
29 100 300 100 300 300 300 100 300
30 300 300 300 –d 300 300 300 300
Phenytoin 30 30 – – – 100 100 100
Carbamazepine 30 100 100 300 – – 100 300
Na-valproate 300 – 300 – 300 – – –
a Doses of 30, 100 and 300 mg kg–1 were administered in 0.5% methylcelluose/water mixture. Numbers in the
table indicate the minimum dose by which bioactivity was demonstrated in half or more of the mice. The
dash (–) indicates the absence of activity at the maximum dose administered (300 mg kg–1).
b In the MES screen, the compound showed protection at 100 mg kg–1 in 1/3 mice.
c In the MES screen, compounds 5 and 10 at 30 mg kg–1 showed protection of 1/3 mice after 1 and 0.25 h, re-
spectively.
d In the scPTZ screen at a dose of 100 mg kg–1, compounds that showed protection were 1, 2, 25 and 27 (0.25
h), 26 (0.25 and 1 h), 28 (0.5 h) and 30 (1 h).
e Compound 2 at 100 mg kg–1 caused death following continuous seizure 1 h period after administration.
f Compounds 1 and 26 showed neurotoxicity at 100 mg kg–1 1 h after administration.
were administered PEG. Phenytoin was used as reference for comparison at a dose of 30
mg kg–1 (p.o., in a 0.5% methylcellulose/water mixture). The observations are tabulated
in Table IV.
CNS depressant study. – The forced swim pool method described earlier was followed
(26). Wistar rats (six animals in each group) were placed in a chamber (diameter 45 cm,
height 20 cm) containing water up to the height of 15 cm at 25 ± 2 °C. Two swim sessions
were conducted, an initial 15 min pre-test, followed by a 5 min test session 24 h later. The
animals were administered an i.p. injection (30 mg kg–1) of the test compound 30 min be-
fore the test session. The period of immobility (passive floating without struggling, mak-
ing only those movements which are necessary to keep its head above the surface) during
the 5 min test period were measured. Carbamazepine was used as a reference for compar-
ison at a dose of 30 mg kg–1 (i.p., in a 0.5% methylcellulose/water mixture). The control
animals were administered PEG. The results are presented in Table V.
Isolation of rat brain regions and GABA assay. – The GABA assay for compounds 2, 26,
27 and 29 was performed in brain tissue extracts enzymatically as previously described
(27). Adult Wistar rats (groups of six animals) were used for this purpose. After 2 h of
drug administration (30 mg kg–1, i.p.), the animal was sacrificed by decapitation, and the
brain regions, mid brain, olfactory lobe, cerebellum and medulla oblongata were drop-
ped into separate vials containing 4–6 mL of ice-cold 80% ethanol and processed further
as described previously (28).
In vitro GABA transaminase activity. – The GABA-T enzyme was prepared from Pseu-
domonas fluorescens according to the method reported earlier (29). The in vitro enzyme in-
hibition assay was performed up to a 4 h period for compounds 2, 26, 27, and 29 accord-
ing to the previously reported procedure (30).
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25 197.67 ± 13.24 120.33 ± 11.35 41.33 ± 3.25
26 282.33 ± 29.08 100.33 ± 13.11 51.17 ± 6.80
27 301.5 ± 27.67 137.33 ± 11.33 93.17 ± 5.93
29 154.83 ± 16.11 70.33 ± 6.43 55 ± 5.99
30 155.17 ± 26.98 60.17 ± 5.04 71 ± 7.45
Phenytoinc 247.32 ± 21.12 104.11 ± 14.56 106.23 ± 12.44
a Compounds were tested at a dose of 100 mg kg–1 (i.p.).
b Each score represents the mean ± SEM of six mice, significantly different from the control score at p < 0.05
(Student’s t test).
c Tested at 30 mg kg–1 (p.o., in 0.5% methylcelluose/water mixture).
d Control animals were administered PEG (i.p.).
RESULTS AND DISCUSSION
All the thirty compounds synthesized, including the intermediates 2,4-dimethylphe-
nyl urea (1) and semicarbazide (2) derivatives, were evaluated for anticonvulsant activ-
ity. The results are presented in Table III, along with the data on phenytoin, carbama-
zepine and sodium valproate. The 2,4-dimethylphenyl urea (1) and the semicarbazide
(2) and some semicarbazone derivatives showed anti-MES activity, indicative of their
ability to prevent seizure spread. At a dose of 100 mg kg–1, compounds that showed pro-
tection in half or more of the tested mice were 1, 2, 26 and 29 after 0.5 h of drug adminis-
tration. Compounds 12, 26, 29 and 30 were capable of preventing seizure spread over a 4
h period at a dose of 300 mg kg–1. All other compounds were inactive. In the rat i.p. MES
screen, compounds 5 and 10 at 30 mg kg–1 showed protection after 1 h and 0.25 h of ad-
ministration, respectively. In the rat oral MES screen (30 mg kg–1), compounds that were
active were 26 (0.5 h) and 27 (0.5, 1 and 2 h).
Compounds 1, 2, 9, 25–27, 29 and 30 were found to be active in the scPTZ test, a test
used to identify compounds that elevate the seizure threshold. Compound 29 showed
activity at a dose of 100 mg kg–1 comparable with carbamazepine and higher potency
than sodium valproate. Death following continuous seizure was observed in one animal
after 1 h of administration of compound 2 (100 mg kg–1), though the compound exhibi-
ted protection after 0.5 h (Table III). All compounds were also evaluated in the scSTY
tests. The activity of compounds 9, 12, 23, 25–27 29 and 30 in the scSTY test showed that
semicarbazones could also act through inhibitory glycine receptors, as reported earlier
(13). Compound 12 was able to prevent scSTY-induced seizure at a dose of 75 mg kg–1
over a 4 h period. Compounds that showed anti-scSTY activity at 100 mg kg–1 include 9
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PEG 143.5 ± 11.42 157.83 ± 10.04NS
25 163.33 ± 8.53 208.33 ± 9.92
26 151 ± 6.39 212.33 ± 6.89
27 142.17 ± 6.27 197.83 ± 8.44
28 147.33 ± 5.82 225.5 ± 6.99
30 139.33 ± 6.67 192.17 ± 6.47
Carbamazepined 131.5 ± 9.32 207.33 ± 8.49
a Compounds were tested at a dose of 100 mg kg–1 (i.p.).
b Control animals were administered PEG (i.p.).
c Each value represents the mean ± SEM of six mice significantly different from the control at p < 0.008
(NS – not significant).
d Tested at 30 mg kg–1 (i.p., in 0.5% methylcelluose/water).
(0.5 h), 27 (0.5 h) and 25 (1 h) at 150 mg kg–1. Compounds 26, 29 and 30 showed protec-
tion at 300 mg kg–1, and compounds 29 and 30 showed loss of the righting reflex after
0.25 h of drug administration.
In the neurotoxicity test, compounds 12 and 28 did not show toxicity at the highest
administered dose of 300 mg kg–1 while compounds 1, 5, 23, 25, 27 and 30 showed lower
toxicity than the standard drugs phenytoin and carbamazepine. Mice were unable to
grasp the rotorod after administration of compounds 2 (300 mg kg–1, 0.5 h), 5 (300 mg
kg–1, 0.5 h), 12 (300 mg kg–1, 0.5 h), 26 (100 mg kg–1, 0.5 h and 1 h and at 300 mg kg–1 0.5
and 4 h) and 30 (300 mg kg–1, 0.5 and 4 h). With compound 29, loss of the righting reflex
was observed after 0.5 and 4 h after a 300 mg kg–1 dose was administered, and with
compound 30 (300 mg kg–1) slight tremors were noted. Compounds 4, 6–8, 10, 11, 13–22
and 24 did not exhibit anticonvulsant activity or neurotoxicity.
The lower levels of neurotoxicity associated with compounds 5, 23, 25–27 and 28
and the absence of toxicity with 4, 6–8, 12–22 and 28 clearly indicate the difference in ac-
tivity due to the carbimino terminal substituents, which were also responsible for the
difference in bioactivity of the semicarbazones. When one of the substituents at the car-
bimino terminal was hydrogen or methyl, the other substituents seemed to be responsi-
ble for the activity. As regards substituents, an electron donating group that increases
the lipophilicity of the ring, as in 9 and 12, showed good protection in MES, scSTY,
scPTZ and scSTY screens, respectively. In the case of compound 5, toxicity was observed
which showed that the compound had sufficient hydrophobicity to cross the blood brain
barrier. As this compound was inactive, the importance of para substitution comes to the
front. But in the case of compound 10, the absence of activity could be attributed to the
fact that the p-OH is highly prone to metabolic attack (O-glucuronide). The para methyl
group in 12 with relatively higher resistance to metabolic attack may have made the
compound active. In general, it appeared that small, lipophilic, non-hydrogen bonding
groups at the 4-position showed activity.
Replacement of the proton in the carbimino carbon atom by methyl (17–23, and 26–29)
or phenyl (24 and 25), leading to an increase in the size of the group at this position of
the molecule, has shown variation in activity. This modification might increase the anti-
convulsant activity due to additional van der Waals bonding or alternatively steric im-
pedance to alignment at a binding site, leading to reduction or abolition of activity (5).
As regards 24 and 25, the former did not show any anticonvulsant activity whereas 25
with a para bromo group showed activity. This is consistent with the report that 4-bromo
phenyl derivatives showed better anticonvulsant activity (3, 13).
Results obtained with levetiracetam in the 6 Hz test suggest that it may identify a
compound that is not active by either the MES or scPTZ test and thus detect active sub-
stances that would have been missed by a more traditional identification procedure (31,
14). In the present study, some selected compounds (5, 6, 10–12 and 22) were screened in
the 6 Hz psychomotor seizure model. Compounds 6, 11 and 12 showed protection in
25% mice at 100 mg kg–1 after 0.5, 2, and 0.25 h, respectively. Recent studies completed
by the anticonvulsant screening program, NIH (23), have revealed that 6 Hz seizures ap-
pear to be somewhat resistant to phenytoin and other sodium channel blockers.
It is conceivable from this study that the structural features essential for interaction
at the binding site were a lipophilic moiety (2,4-dimethylphenyl ring) and a hydrogen
bonding domain (amide function, NHCO), as proposed earlier (32). The distal aryl ring
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at the carbimino terminal (benzylidene ring) may be essential for the pharmacokinetic
properties of the compounds, since variation in the substituents at the distal aryl ring
was found to affect the biological activity.
In the behavioral despair test, some selected compounds (26–28, 30) were tested and
were found to decrease the motor activity, as indicated by the actophotometer scores
(Table IV). Similar results were obtained in Porsolt’s swim pool test with compounds 26
and 27 and 29 and 30, in which an increase in the immobility time by the compounds
indicated the CNS depression effect (Table V).
In order to explore the mechanism of anticonvulsant activity, some selected com-
pounds that were highly active were subjected to neurochemical investigation to study
their effects on the levels of GABA in different regions of rat brain, viz., mid brain, olfac-
tory lobe, cerebellum, and medulla oblongata. Compounds 2 and 27 showed an increase
of GABA levels in the olfactory lobe and cerebellum, while compounds 26 and 29 show-
ed a significant increase in GABA levels in the mid brain region of rat brain (Table VI).
These compounds did not have a significant effect on the GABA levels in medulla ob-
longata. Further, compounds 2, 26, 27 and 29 were carried on to preliminary in vitro
GABA-T (Pseudomonas fluorescens) inhibition studies. Compound 2 and 27 emerged as
potent inhibitors of the enzyme (90 and 89%, respectively) and 26 and 29 showed 44 and
57% inhibition, respectively. These studies confirm our earlier report (19) on aryl semi-
carbazones acting through a GABA-mediated mechanism. These data corroborate that
the compounds align at a specific binding site and are not structurally nonspecific.
CONCLUSIONS
The presented results indicated that the 2,4-dimethylphenyl semicarbazones were
effective in MES, scPTZ and scSTY models and were found to act through GABA-media-
tion.
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In vitro GABA-T activity












Controld 46.49 ± 3.34 14.85 ± 1.03 29.54 ± 1.85 47.89 ± 9.15 – – –
2 48.91 ± 3.77 29.79 ± 0.93a 45.54 ± 2.20a 38.77 ± 11.25 62.5 3 90
26 63.39 ± 2.77a 19.79 ± 3.22 19.36 ± 2.22a 37.64 ± 6.77 250 4 44
27 36.09 ± 5.05 27.85 ± 2.89b 38.92 ± 3.34c 46.87 ± 3.34 62.5 3 89
29 102.27 ± 11.37a 18.71 ± 0.63 25.82 ± 3.46 41.08 ± 2.96 125 3 51
Each value represents the mean  SEM of six rats significantly different from the control at a p < 0.01,
b p < 0.02, c p < 0.03.
d Control animals were administered PEG (i.p.).
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S A @ E T A K
Sinteza N4-(2,4-dimetilfenil) semikarbazona kao inhibitora 4-aminobutirat
aminotransferaze
PERUMAL YOGEESWARI, DHARMARAJAN SRIRAM, RATHINASABAPATHY THIRUMURUGAN,
LOGANTHA RAMAMOORTHY JEEWANLAL SUNIL JIT, JEGADEESAN VAIGUNDA RAGAVENDRAN,
RAMKUMAR KAVYA, KAVYA RAKHRA i VIVEK SARASWAT
Sintetizirano je nekoliko 2,4-dimetilfenil supstituiranih semikarbazona u tri sintet-
ska koraka koji uklju~uju aril uree i aril semikarbazide. Strukture spojeva su potvr|ene
spektroskopskim metoda i elementarnom analizom. Ispitano je antikonvulzivno djelo-
vanje novih spojeva nakon izazivanja konvulzija elektro{okom te supkutanom primje-
nom pentilentetrazola ili strihnina. Osim toga, testirano je antidepresivno djelovanje te
u~inak tih spojeva na pona{anje {takora. Pra}en je njihov utjecaj na koncentraciju -ami-
nomasla~ne kiseline (GABA) u mozgu {takora te in vitro na aktivnost -aminobutirat
transaminaze (Pseudomonas fluorescens). Preliminarni pokusi ukazuju da antikonvulziv-
no djelovanje ovih spojeva uklju~uje GABA-ergi~ki sustav.
Klju~ne rije~i: 2,4-dimetilfenil semikarbazoni, antikonvulzivi, GABA, GABA-transaminaza, maksi-
malni elektro{ok, pentilentetrazol, strihnin
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